BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 36648324)

  • 21. Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma.
    Pirosa MC; Stathis A; Zucca E
    Hum Vaccin Immunother; 2024 Dec; 20(1):2309701. PubMed ID: 38299612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
    Goy A; Ramchandren R; Ghosh N; Munoz J; Morgan DS; Dang NH; Knapp M; Delioukina M; Kingsley E; Ping J; Beaupre DM; Neuenburg JK; Ruan J
    Blood; 2019 Sep; 134(13):1024-1036. PubMed ID: 31331917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context.
    Abdulhaq H; Hwang A; Mahmood O
    Onco Targets Ther; 2023; 16():617-629. PubMed ID: 37492075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Broadening the MIND: Tafasitamab and Lenalidomide versus Synthetic Controls.
    Cherng HJ; Westin JR
    Clin Cancer Res; 2022 Sep; 28(18):3908-3910. PubMed ID: 35861632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic evaluation of polatuzumab-bendamustine-rituximab
    Calamia M; McBride A; Abraham I
    J Med Econ; 2021 Nov; 24(sup1):14-24. PubMed ID: 34866523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of tafasitamab in diffuse large B-cell lymphoma.
    Düll J; Topp M; Salles G
    Ther Adv Hematol; 2021; 12():20406207211027458. PubMed ID: 34285786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Second-line treatment of diffuse large B-cell lymphoma: Evolution of options.
    Fabbri N; Mussetti A; Sureda A
    Semin Hematol; 2023 Nov; 60(5):305-312. PubMed ID: 38342663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Harris LJ; Patel K; Martin M
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatments for relapsed-refractory diffuse large B-cell lymphoma: comparison of overall survival outcomes observed with four novel agents.
    Messori A; Caccese E
    Eur Rev Med Pharmacol Sci; 2022 Jul; 26(13):4666-4670. PubMed ID: 35856357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.
    Palazón-Carrión N; Martín García-Sancho A; Nogales-Fernández E; Jiménez-Cortegana C; Carnicero-González F; Ríos-Herranz E; de la Cruz-Vicente F; Rodríguez-García G; Fernández-Álvarez R; Martínez-Banaclocha N; Gumà-Padrò J; Gómez-Codina J; Salar-Silvestre A; Rodríguez-Abreu D; Gálvez-Carvajal L; Labrador J; Guirado-Risueño M; García-Domínguez DJ; Hontecillas-Prieto L; Espejo-García P; Fernández-Román I; Provencio-Pulla M; Sánchez-Beato M; Navarro M; Marylene L; Álvaro-Naranjo T; Casanova-Espinosa M; Sánchez-Margalet V; Rueda-Domínguez A; de la Cruz-Merino L
    Clin Cancer Res; 2022 Sep; 28(17):3658-3668. PubMed ID: 35727601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transformed Waldenström Macroglobulinemia Responsive to Tafasitamab Plus Lenalidomide: A Case Report.
    Nasir SA; Pandya D; Wojkiewicz S; Khandpur B; Downes E; Pathare P; Frank R
    Cureus; 2022 Dec; 14(12):e32403. PubMed ID: 36636536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma.
    Ward JP; Berrien-Elliott MM; Gomez F; Luo J; Becker-Hapak M; Cashen AF; Wagner-Johnston ND; Maddocks K; Mosior M; Foster M; Krysiak K; Schmidt A; Skidmore ZL; Desai S; Watkins MP; Fischer A; Griffith M; Griffith OL; Fehniger TA; Bartlett NL
    Blood; 2022 Mar; 139(13):1999-2010. PubMed ID: 34780623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma.
    Zinzani PL; Minotti G
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):177-190. PubMed ID: 34741682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B-Cell lymphoma -results of a single center, retrospective cohort in China.
    Wang Y; Xue H; Song W; Xiao S; Jing F; Dong T; Wang L
    Hematol Oncol; 2022 Oct; 40(4):617-625. PubMed ID: 35165928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation.
    Ferreri AJM; Sassone M; Angelillo P; Zaja F; Re A; Di Rocco A; Spina M; Fabbri A; Stelitano C; Frezzato M; Volpetti S; Zambello R; Rusconi C; De Lorenzo D; Scarano E; Arcari A; Bertoldero G; Nonis A; Calimeri T; Perrone S; Cecchetti C; Tarantino V; Steffanoni S; Foppoli M; Ciceri F; Ponzoni M
    Hematol Oncol; 2020 Aug; 38(3):257-265. PubMed ID: 32356913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lenalidomide combined with R-GDP in a patient with refractory CD5-positive diffuse large B-cell lymphoma: A promising response and review.
    Zhang Y; Wang X; Liu Y; Sun C; Shi W; Huang H
    Cancer Biol Ther; 2018 Jul; 19(7):549-553. PubMed ID: 29611764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel agents in relapsed/refractory diffuse large B-cell lymphoma.
    Varma G; Goldstein J; Advani RH
    Hematol Oncol; 2023 Jun; 41 Suppl 1():92-106. PubMed ID: 37294966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma.
    Brooks TR; Caimi PF
    Blood Rev; 2024 Jan; 63():101140. PubMed ID: 37949705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lenalidomide in DLBCL: are we past the cell of origin?
    Goldfinger M; Cooper DL
    Clin Adv Hematol Oncol; 2021 May; 19(5):320-325. PubMed ID: 33989279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.